BTIG Research initiated coverage on Lucid Diagnostics with a new price target
$LUCD
Medical/Dental Instruments
Health Care
BTIG Research initiated coverage of Lucid Diagnostics with a rating of Buy and set a new price target of $14.00
Get the next $LUCD alert in real time by email
Get the next $LUCD alert in real time by email
Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $LUCD
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/27/2021 | $16.00 | Buy | Ascendiant Capital |
| 12/15/2021 | $17.00 → $13.00 | Buy | Needham |
| 11/8/2021 | $18.00 | Buy | Canaccord Genuity |
| 11/8/2021 | $14.00 | Buy | BTIG Research |
| 11/8/2021 | $21.00 | Overweight | Cantor Fitzgerald |
| 11/8/2021 | $17.00 | Buy | Needham |
Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
NEW YORK, April 3, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10, 2025 at 11:00 AM EDT. The fireside chat will be webcast live and can be accessed by visiting the Investor Relations Section of the Lucid Diagnostics website or by c
Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology
Campaign will coincide with Esophageal Cancer Awareness Month and will be featured at the upcoming Digestive Disease Week (DDW) Conference NEW YORK, March 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced a campaign, entitled "Embrace the Future", designed to showcase its groundbreaking EsoCheck® Esophageal Cell Collection Device, with Collect+Protect™ Technology, to gastroenterologists and the broader medical community. The campaign will coincide with Esophageal Cancer Awareness Month this April and will be prominently featur
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Lucid processed record test volume, saw rapid initial uptake in concierge medicine contracts, and secured first commercial insurance coverage policies Veris Health secured financing to resume advancement of implantable physiological monitor through FDA clearance and commercial launch PAVmed completed debt restructuring and Lucid deconsolidation to regain Nasdaq compliance and strengthen balance sheet Conference call and webcast to be held today, March 25th, at 8:30 AM EDT NEW YORK, March 25, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital
Ascendiant Capital initiated coverage on Lucid Diagnostics with a new price target
Ascendiant Capital initiated coverage of Lucid Diagnostics with a rating of Buy and set a new price target of $16.00
Needham reiterated coverage on Lucid Diagnostics with a new price target
Needham reiterated coverage of Lucid Diagnostics with a rating of Buy and set a new price target of $13.00 from $17.00 previously
Canaccord Genuity initiated coverage on Lucid Diagnostics with a new price target
Canaccord Genuity initiated coverage of Lucid Diagnostics with a rating of Buy and set a new price target of $18.00
President and COO O'Neil Shaun was granted 300,000 shares, increasing direct ownership by 57% to 826,763 units (SEC Form 4)
4 - Lucid Diagnostics Inc. (0001799011) (Issuer)
Chief Executive Officer Aklog Lishan was granted 300,000 shares, increasing direct ownership by 26% to 1,466,627 units (SEC Form 4)
4 - Lucid Diagnostics Inc. (0001799011) (Issuer)
Director Sokolov Jacque J was granted 112,800 shares, increasing direct ownership by 133% to 197,460 units (SEC Form 4)
4 - Lucid Diagnostics Inc. (0001799011) (Issuer)
Lucid Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Lucid Diagnostics Inc. (0001799011) (Filer)
SEC Form 10-K filed by Lucid Diagnostics Inc.
10-K - Lucid Diagnostics Inc. (0001799011) (Filer)
Lucid Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure
8-K - Lucid Diagnostics Inc. (0001799011) (Filer)
PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements
Efforts include appointment of seasoned biotech investor Sundeep Agrawal, M.D. to board to replace departing directors NEW YORK, Sept. 16, 2024 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that, as part of its efforts to regain compliance with Nasdaq's listing requirements, Lucid Diagnostics (NASDAQ:LUCD) ("Lucid") will be deconsolidated from PAVmed's financial statements. As a result, PAVmed will no longer report consolidated financials reflecting Lucid's operating losses. PAVmed's holdings of Lucid common stock remain
Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors
Final closing yields total gross proceeds of $29.8 million from offering Mr. Matheis serves as President and CEO of Sentara Health, one of the largest not-for-profit integrated health systems in the U.S., which encompasses hospitals, a physician group, and an affiliated health plan NEW YORK, May 7, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the Company has closed a Series B-1 Preferred Stock offering led by one of the Company's long-time institutional investors, with gross proceeds of $11.6 million, bringing
PAVmed Digital Health Subsidiary, Veris Health, Appoints Gary Manning as President
Manning Brings Vast Digital Health Experience Focused on Demonstrable Growth and Commercial Excellence NEW YORK, April 25, 2023 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ))) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), today announced the appointment of Gary Manning to the newly created position of President, Veris Health. Mr. Manning reports directly to Lishan Aklog, M.D., PAVmed's Chairman & Chief Executive Officer and Veris' Executive Chairman.
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Lucid processed record test volume, saw rapid initial uptake in concierge medicine contracts, and secured first commercial insurance coverage policies Veris Health secured financing to resume advancement of implantable physiological monitor through FDA clearance and commercial launch PAVmed completed debt restructuring and Lucid deconsolidation to regain Nasdaq compliance and strengthen balance sheet Conference call and webcast to be held today, March 25th, at 8:30 AM EDT NEW YORK, March 25, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Processed a record 4,042 EsoGuard tests in 4Q24, a 45% sequential and 84% annual increase Recognized EsoGuard revenue of $1.2 million in 4Q24 New sales channel generated over 20 new cash-pay concierge medicine contracts Secured first agreement to pay for EsoGuard under state biomarker legislation Conference call and webcast to be held today, March 24th at 8:30 AM EDT NEW YORK, March 24, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) ("PAVmed"), today provided a business update for the Company and reported financial results for the four
PAVmed to Hold a Business Update Conference Call and Webcast on March 25, 2025
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, March 11, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ), PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Tuesday, March 25, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the C
Amendment: SEC Form SC 13D/A filed by Lucid Diagnostics Inc.
SC 13D/A - Lucid Diagnostics Inc. (0001799011) (Subject)
Amendment: SEC Form SC 13G/A filed by Lucid Diagnostics Inc.
SC 13G/A - Lucid Diagnostics Inc. (0001799011) (Subject)
SEC Form SC 13D/A filed by Lucid Diagnostics Inc. (Amendment)
SC 13D/A - Lucid Diagnostics Inc. (0001799011) (Subject)